PMV Pharmaceuticals (PMVP)

PMV Pharmaceuticals Stock Analysis & Ratings

PMVP Stock Chart & Stats

Day’s Range$12.94 - $14.21
52-Week Range$11.44 - $37.32
Previous Close$12.65
Average Volume (3M)874.14K
Market Cap$637.13M
P/E Ratio-9.9
Next EarningsAug 12, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)-1.28



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was PMV Pharmaceuticals’s price range in the past 12 months?
PMV Pharmaceuticals lowest stock price was $11.44 and its highest was $37.32 in the past 12 months.
    What is PMV Pharmaceuticals’s market cap?
    PMV Pharmaceuticals’s market cap is $637.13M.
      What is PMV Pharmaceuticals’s price target?
      The average price target for PMV Pharmaceuticals is $43.25. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $63.00 ,the lowest forecast is $30.00. The average price target represents 209.37% Increase from the current price of $13.98.
        What do analysts say about PMV Pharmaceuticals?
        PMV Pharmaceuticals’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is PMV Pharmaceuticals’s upcoming earnings report date?
          PMV Pharmaceuticals’s upcoming earnings report date is Aug 12, 2022 which is in 87 days.
            How were PMV Pharmaceuticals’s earnings last quarter?
            PMV Pharmaceuticals released its earnings results on May 10, 2022. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.019.
              Is PMV Pharmaceuticals overvalued?
              According to Wall Street analysts PMV Pharmaceuticals’s price is currently Undervalued.
                Does PMV Pharmaceuticals pay dividends?
                PMV Pharmaceuticals does not currently pay dividends.
                What is PMV Pharmaceuticals’s EPS estimate?
                PMV Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does PMV Pharmaceuticals have?
                PMV Pharmaceuticals has 45,570,000 shares outstanding.
                  What happened to PMV Pharmaceuticals’s price movement after its last earnings report?
                  PMV Pharmaceuticals reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went up 9.659%.
                    Which hedge fund is a major shareholder of PMV Pharmaceuticals?
                    Among the largest hedge funds holding PMV Pharmaceuticals’s share is RA Capital Management. It holds PMV Pharmaceuticals’s shares valued at 36M.


                      PMV Pharmaceuticals Stock Analysis

                      The PMV Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      PMV Pharmaceuticals

                      PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.

                      Similar Stocks
                      No data currently available

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis